Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Clark Atlanta University maintains 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution is handled by 1 distinct examiner and 1 distinct art unit. Kristen Wang Romero is the busiest examiner, overseeing the 1 pending office action currently on record.
This indicates a specific biotechnological research focus for the university's current patenting activity. Practitioners should note that the current examination is confined to 1 art unit, which may simplify the coordination of prosecution strategies. This focused distribution reflects a specific technological scope for the university's current patenting efforts. The alignment of the workload under a single examiner indicates a narrow point of contact within the patent office. The absence of multiple pending matters suggests that the university is prioritizing specific innovations within the Biotechnology & Pharmaceuticals sector. Such a concentrated profile may result in more predictable prosecution timelines compared to portfolios spread across numerous art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROMERO, KRISTEN WANG | 1 | 69.8% | +30.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18907903 | Small Molecules G(alpha)I2 Inhibitors and Combination With Anticancer Drugs and Use Thereof | ROMERO, KRISTEN WANG | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18907903 | Small Molecules G(alpha)I2 Inhibitors and Combination With Anticancer Drugs and Use Thereof | ROMERO, KRISTEN WANG | 1624 | §103§112DP | Non-Final OA | — | Pending | Oct 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialClark Atlanta University has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kristen Wang Romero has the most, with 1 of Clark Atlanta University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
